Abstract Purpose of Review Over the past two decades, the introduction of tyrosine kinase
inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four …

Introduction: Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder
distinctly characterized by the presence of the Philadelphia chromosome, which results from …

The advent of tyrosine kinase inhibitors (TKIs) has dramatically improved the outcome of
patients with chronic myeloid leukemia (CML). Currently, four TKIs are available for the …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia
(CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled …

The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic
myeloid leukemia (CML). For patient with chronic phase CML, frontline treatment with …

The efficacy of second‐line treatment for chronic myeloid leukemia (CML) plays an important
role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

Introduction: The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for
chronic myeloid leukemia (CML). However, there are many topics related to therapy that …